Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
A phase 1/2 trial of Autologous CD19/CD22 dual-target CAR-T module in acute lymphoblastic leukaemia, non-Hodgkin lymphoma, multiple myeloma, acute myeloid leukaemia and peripheral T-cell lymphomas, run by Beijing Biotech, now recruiting.
Overview
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies is a phase 1/2 interventional study registered as NCT07523555 by Beijing Biotech, with 96 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module, Autologous BCMA/CD38 dual-target CAR-T module, Autologous BCMA/GPRC5D dual-target CAR-T and Autologous CD33/CD123 dual-target CAR-T module.
Similar pages
not linked directly; found by shared links- TrialA Study of CTD402 in T-ALL/LBL Patients
Shares Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Non-Hodgkin lymphoma (all types), Multiple myeloma and the tag pipeline.
- TrialValemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialSafety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Shares Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag pipeline.
- TrialTGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Shares Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag pipeline.
- TrialStudy of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Shares Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag pipeline.
- TrialA Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Shares Non-Hodgkin lymphoma (all types), Multiple myeloma and the tag pipeline.